|
|
| Line 1: |
Line 1: |
| | + | '''Unreleased structure''' |
| | | | |
| - | ==Structure of the active form of ScpB, the C5a-peptidase from Streptococcus agalactiae.==
| + | The entry 8bty is ON HOLD until Paper Publication |
| - | <StructureSection load='8bty' size='340' side='right'caption='[[8bty]], [[Resolution|resolution]] 1.70Å' scene=''>
| + | |
| - | == Structural highlights ==
| + | |
| - | <table><tr><td colspan='2'>[[8bty]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Streptococcus_agalactiae Streptococcus agalactiae]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8BTY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8BTY FirstGlance]. <br>
| + | |
| - | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.7Å</td></tr>
| + | |
| - | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=EPE:4-(2-HYDROXYETHYL)-1-PIPERAZINE+ETHANESULFONIC+ACID'>EPE</scene>, <scene name='pdbligand=MLA:MALONIC+ACID'>MLA</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
| + | |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8bty FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8bty OCA], [https://pdbe.org/8bty PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8bty RCSB], [https://www.ebi.ac.uk/pdbsum/8bty PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8bty ProSAT]</span></td></tr>
| + | |
| - | </table>
| + | |
| - | == Function ==
| + | |
| - | [https://www.uniprot.org/uniprot/Q53637_STRAG Q53637_STRAG] This virulence factor of S.pyogenes specifically cleaves the human serum chemotaxin C5a at '68-Lys-|-Asp-69' bond near its C-terminus, destroying its ability to serve as a chemoattractant.[ARBA:ARBA00002909]
| + | |
| - | <div style="background-color:#fffaf0;">
| + | |
| - | == Publication Abstract from PubMed ==
| + | |
| - | A 1.7 A structure is presented for an active form of the virulence factor ScpB, the C5a peptidase from Streptococcus agalactiae. The previously reported structure of the ScpB active site mutant exhibited a large separation (~20 A) between the catalytic His and Ser residues. Significant differences are observed in the catalytic domain between the current and mutant ScpB structures resulting with a high RMSD(Calpha) (4.6 A). The fold of the active form of ScpB is nearly identical to ScpA (RMSD(Calpha) 0.2 A), the C5a-peptidase from Streptococcus pyogenes. Both ScpA and ScpB have comparable activity against human C5a, indicating neither enzyme require host proteins for C5a-ase activity. These studies are a first step in resolving reported differences in the specificities of these enzymes.
| + | |
| | | | |
| - | The 1.7 A crystal structure of the C5a peptidase from Streptococcus agalactiae (ScpB) reveals an active site competent for catalysis.,Cullen R, Tecza M, Miclot T, Behan S, Jain M, Avink MK, Cooney JC, Kagawa TF Proteins. 2023 Nov 3. doi: 10.1002/prot.26625. PMID:37921533<ref>PMID:37921533</ref>
| + | Authors: |
| | | | |
| - | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
| + | Description: |
| - | </div>
| + | [[Category: Unreleased Structures]] |
| - | <div class="pdbe-citations 8bty" style="background-color:#fffaf0;"></div>
| + | |
| - | == References ==
| + | |
| - | <references/>
| + | |
| - | __TOC__
| + | |
| - | </StructureSection>
| + | |
| - | [[Category: Large Structures]] | + | |
| - | [[Category: Streptococcus agalactiae]]
| + | |
| - | [[Category: Cooney JC]]
| + | |
| - | [[Category: Cullen R]]
| + | |
| - | [[Category: Kagawa TF]]
| + | |
| - | [[Category: Miclot T]]
| + | |
